Genomma Lab Internacional, S.A.B. de C.V. GNMLF
OTC PK
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 260.66M | 253.02M | 238.44M | 219.50M | 489.68M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 260.66M | 253.02M | 238.44M | 219.50M | 489.68M |
| Cost of Revenue | 100.58M | 89.68M | 87.23M | 85.66M | 177.89M |
| Gross Profit | 160.08M | 163.34M | 151.21M | 133.83M | 311.79M |
| SG&A Expenses | 110.45M | 113.10M | 101.54M | 86.77M | 209.25M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -428.40K | -240.00K | -81.90K | 3.04M | -4.78M |
| Total Operating Expenses | 210.60M | 202.54M | 188.69M | 175.48M | 382.36M |
| Operating Income | 50.05M | 50.48M | 49.75M | 44.02M | 107.33M |
| Income Before Tax | 40.53M | 30.77M | 36.65M | 31.05M | 62.53M |
| Income Tax Expenses | 10.69M | 9.22M | 8.50M | 13.22M | 20.16M |
| Earnings from Continuing Operations | 29.84M | 21.55M | 28.14M | 17.83M | 42.38M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 29.84M | 21.55M | 28.14M | 17.83M | 42.38M |
| EBIT | 50.05M | 50.48M | 49.75M | 44.02M | 107.33M |
| EBITDA | 55.26M | 55.68M | 54.91M | 49.20M | 112.44M |
| EPS Basic | 0.02 | 0.02 | 0.03 | 0.02 | 0.07 |
| Normalized Basic EPS | 0.02 | 0.02 | 0.02 | 0.02 | 0.07 |
| EPS Diluted | 0.02 | 0.02 | 0.03 | 0.02 | 0.07 |
| Normalized Diluted EPS | 0.02 | 0.02 | 0.02 | 0.02 | 0.07 |
| Average Basic Shares Outstanding | 1.47B | 985.51M | 969.90M | 978.15M | 597.75M |
| Average Diluted Shares Outstanding | 1.47B | 985.51M | 969.90M | 978.15M | 597.75M |
| Dividend Per Share | -- | 0.01 | 0.01 | 0.01 | 0.01 |
| Payout Ratio | 37.81% | 52.07% | 39.49% | 59.88% | 49.56% |